$ADVM
Adverum Biotechnologies, Inc.

2016 Q2 Form 10-Q Financial Statement

#000156459016023738 Filed on August 09, 2016

View on sec.gov

Income Statement

Concept 2016 Q2 2015 Q2
Revenue $307.0K $203.0K
YoY Change 51.23% 50.37%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $5.110M $4.960M
YoY Change 3.02% 232.89%
% of Gross Profit
Research & Development $7.960M $5.126M
YoY Change 55.29% 65.68%
% of Gross Profit
Depreciation & Amortization $340.0K $150.0K
YoY Change 126.67% 650.0%
% of Gross Profit
Operating Expenses $62.19M $10.09M
YoY Change 516.65% 119.81%
Operating Profit -$61.88M -$9.882M
YoY Change 526.21% 121.92%
Interest Expense $0.00
YoY Change -100.0%
% of Operating Profit
Other Income/Expense, Net $222.0K $116.0K
YoY Change 91.38% -118.1%
Pretax Income -$61.66M -$9.770M
YoY Change 531.12% 91.94%
Income Tax
% Of Pretax Income
Net Earnings -$61.66M -$9.766M
YoY Change 531.37% 91.72%
Net Earnings / Revenue -20084.69% -4810.84%
Basic Earnings Per Share
Diluted Earnings Per Share -$1.760M -$382.2K
COMMON SHARES
Basic Shares Outstanding 25.53M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2016 Q2 2015 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $241.3M $279.6M
YoY Change -13.7% 433.59%
Cash & Equivalents $241.3M $200.5M
Short-Term Investments $0.00 $79.10M
Other Short-Term Assets $1.200M $1.000M
YoY Change 20.0% 100.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $243.6M $280.6M
YoY Change -13.2% 430.46%
LONG-TERM ASSETS
Property, Plant & Equipment $4.000M $2.945M
YoY Change 35.82% 478.59%
Goodwill
YoY Change
Intangibles $16.65M
YoY Change
Long-Term Investments
YoY Change
Other Assets $100.0K $138.0K
YoY Change -27.54% -89.97%
Total Long-Term Assets $20.70M $3.083M
YoY Change 571.42% 63.55%
TOTAL ASSETS
Total Short-Term Assets $243.6M $280.6M
Total Long-Term Assets $20.70M $3.083M
Total Assets $264.3M $283.7M
YoY Change -6.84% 417.83%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.400M $1.896M
YoY Change 26.58% 20.3%
Accrued Expenses $4.100M $3.600M
YoY Change 13.89% 125.0%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $7.900M $7.864M
YoY Change 0.46% 97.04%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change -100.0%
Other Long-Term Liabilities $6.700M $5.200M
YoY Change 28.85% -27.78%
Total Long-Term Liabilities $6.700M $5.200M
YoY Change 28.85% -33.33%
TOTAL LIABILITIES
Total Short-Term Liabilities $7.900M $7.864M
Total Long-Term Liabilities $6.700M $5.200M
Total Liabilities $16.69M $13.09M
YoY Change 27.52% 11.39%
SHAREHOLDERS EQUITY
Retained Earnings -$161.2M -$55.99M
YoY Change 187.94% 209.87%
Common Stock $408.9M $326.6M
YoY Change 25.19%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $247.7M $270.6M
YoY Change
Total Liabilities & Shareholders Equity $264.3M $283.7M
YoY Change -6.83% 417.83%

Cashflow Statement

Concept 2016 Q2 2015 Q2
OPERATING ACTIVITIES
Net Income -$61.66M -$9.766M
YoY Change 531.37% 91.72%
Depreciation, Depletion And Amortization $340.0K $150.0K
YoY Change 126.67% 650.0%
Cash From Operating Activities -$8.230M -$9.250M
YoY Change -11.03% -261.43%
INVESTING ACTIVITIES
Capital Expenditures -$1.010M -$1.080M
YoY Change -6.48% 157.14%
Acquisitions
YoY Change
Other Investing Activities $3.450M $8.900M
YoY Change -61.24%
Cash From Investing Activities $2.440M $7.830M
YoY Change -68.84% -1964.29%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 90.00K 110.0K
YoY Change -18.18% -99.77%
NET CHANGE
Cash From Operating Activities -8.230M -9.250M
Cash From Investing Activities 2.440M 7.830M
Cash From Financing Activities 90.00K 110.0K
Net Change In Cash -5.700M -1.310M
YoY Change 335.11% -102.51%
FREE CASH FLOW
Cash From Operating Activities -$8.230M -$9.250M
Capital Expenditures -$1.010M -$1.080M
Free Cash Flow -$7.220M -$8.170M
YoY Change -11.63% -232.85%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2016Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2016Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
4000
CY2016Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-161220000
CY2016Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
264345000
CY2016Q2 us-gaap Common Stock Value
CommonStockValue
4000
CY2016Q2 us-gaap Preferred Stock Value
PreferredStockValue
CY2016Q2 us-gaap Liabilities
Liabilities
16691000
CY2016Q2 us-gaap Stockholders Equity
StockholdersEquity
247654000
CY2016Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
408866000
CY2016Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2016Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
41322357
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-406000
CY2016Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2016Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2016Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2016Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2016Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2016Q2 us-gaap License And Services Revenue
LicenseAndServicesRevenue
307000
CY2016Q2 us-gaap Operating Expenses
OperatingExpenses
62189000
CY2016Q2 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
16650000
CY2016Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
41322357
CY2016Q2 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
49120000
CY2016Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
222000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
265000
us-gaap Share Based Compensation
ShareBasedCompensation
1332000
CY2016Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-61882000
CY2016Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
222000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
19954000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
41133000
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
159404000
CY2015Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
200537000
us-gaap Straight Line Rent
StraightLineRent
-230000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
131000
us-gaap Business Combination Consideration Transferred1
BusinessCombinationConsiderationTransferred1
64845000
advm Fixed Assets In Accounts Payable And Accrued Expenses And Other Current Liabilities
FixedAssetsInAccountsPayableAndAccruedExpensesAndOtherCurrentLiabilities
153000
advm Fixed Assets In Accounts Payable And Accrued Expenses And Other Current Liabilities
FixedAssetsInAccountsPayableAndAccruedExpensesAndOtherCurrentLiabilities
875000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
349000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
349000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
139085000
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations
EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations
-79000
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations
EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations
-6000
us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
580000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
47000
advm Increase Decrease In Deposit And Other Noncurrent Assets
IncreaseDecreaseInDepositAndOtherNoncurrentAssets
1000
us-gaap Increase Decrease In Restructuring Reserve
IncreaseDecreaseInRestructuringReserve
-988000
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-16992000
us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
88429000
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
37738000
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
8960000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1126000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1485000
us-gaap Cash Acquired From Acquisition
CashAcquiredFromAcquisition
3449000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
40061000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-80954000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
138954000
dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2006-07-17
dei Entity Information Date To Change Former Legal Or Registered Name
EntityInformationDateToChangeFormerLegalOrRegisteredName
2016-05-12
CY2015Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
2369375
CY2015Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
130600000
CY2015Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
8300000
CY2015Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
230000
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2016Q2 us-gaap Availableforsale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions1
AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1
0
CY2015Q4 advm Cash And Cash Equivalent Amortized Cost
CashAndCashEquivalentAmortizedCost
208588000
CY2015Q4 advm Cash And Cash Equivalent Gross Unrealized Gain
CashAndCashEquivalentGrossUnrealizedGain
0
CY2015Q4 advm Cash And Cash Equivalent Gross Unrealized Loss
CashAndCashEquivalentGrossUnrealizedLoss
0
CY2015Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
208588000
CY2015Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
37738000
CY2015Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
6000
us-gaap Maturities Of Time Deposits Description
MaturitiesOfTimeDepositsDescription
Less than one year
us-gaap Proceeds From Sale Of Available For Sale Securities
ProceedsFromSaleOfAvailableForSaleSecurities
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet
0
CY2015 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet
0
CY2015Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
246320000
CY2016Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
5639000
CY2015Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
4178000
CY2016Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1654000
CY2015Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
991000
CY2016Q2 us-gaap Depreciation And Amortization
DepreciationAndAmortization
343000
CY2015Q2 us-gaap Depreciation And Amortization
DepreciationAndAmortization
147000
CY2016Q2 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
1608000
CY2015Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
2047000
CY2016Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
608000
CY2015Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1177000
CY2016Q2 advm Accrued Preclinical Costs
AccruedPreclinicalCosts
1844000
CY2015Q4 advm Accrued Preclinical Costs
AccruedPreclinicalCosts
642000
CY2015Q4 advm Accrued Clinical And Development Process Costs
AccruedClinicalAndDevelopmentProcessCosts
101000
CY2016Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
84000
CY2015Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
40000
CY2016Q2 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
0
us-gaap Loss Contingency Damages Paid Value
LossContingencyDamagesPaidValue
0
us-gaap Loss Contingency New Claims Filed Number
LossContingencyNewClaimsFiledNumber
0
us-gaap Loss Contingency Accrual Provision
LossContingencyAccrualProvision
0
CY2015Q3 us-gaap Loss Contingency New Claims Filed Number
LossContingencyNewClaimsFiledNumber
3
CY2015Q4 us-gaap Loss Contingency New Claims Filed Number
LossContingencyNewClaimsFiledNumber
1
advm Share Based Compensation Arrangement By Share Based Payment Award Options Difference Between Options Exercise Price And Closing Price Of Common Stock Intrinsic Value Amount
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsDifferenceBetweenOptionsExercisePriceAndClosingPriceOfCommonStockIntrinsicValueAmount
3.16
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.62
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
27.90
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
6300000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
10600000
CY2016Q2 advm Allocated Share Based Compensation Expense And Recoveries
AllocatedShareBasedCompensationExpenseAndRecoveries
2826000
CY2015Q2 advm Allocated Share Based Compensation Expense And Recoveries
AllocatedShareBasedCompensationExpenseAndRecoveries
559000
advm Allocated Share Based Compensation Expense And Recoveries
AllocatedShareBasedCompensationExpenseAndRecoveries
6910000
advm Allocated Share Based Compensation Expense And Recoveries
AllocatedShareBasedCompensationExpenseAndRecoveries
1332000
CY2016Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Plan Modification Number Of Employees Affected
ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected
3
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Plan Modification Number Of Employees Affected
ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected
3
CY2016Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.81
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.76
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.81
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.77
CY2016Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y10M24D
CY2015Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y10M24D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y1M6D
CY2016Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.013
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.016
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.013
CY2016Q2 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
236821000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.016
CY2016Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
18400000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P3Y
CY2016Q2 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
100000
CY2015Q2 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
0
us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
200000
us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
100000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9900000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5200000

Files In Submission

Name View Source Status
0001564590-16-023738-index-headers.html Edgar Link pending
0001564590-16-023738-index.html Edgar Link pending
0001564590-16-023738.txt Edgar Link pending
0001564590-16-023738-xbrl.zip Edgar Link pending
advm-10q_20160630.htm Edgar Link pending
advm-20160630.xml Edgar Link completed
advm-20160630.xsd Edgar Link pending
advm-20160630_cal.xml Edgar Link unprocessable
advm-20160630_def.xml Edgar Link unprocessable
advm-20160630_lab.xml Edgar Link unprocessable
advm-20160630_pre.xml Edgar Link unprocessable
advm-ex1010_292.htm Edgar Link pending
advm-ex103_297.htm Edgar Link pending
advm-ex104_296.htm Edgar Link pending
advm-ex105_294.htm Edgar Link pending
advm-ex106_295.htm Edgar Link pending
advm-ex107_192.htm Edgar Link pending
advm-ex108_191.htm Edgar Link pending
advm-ex109_293.htm Edgar Link pending
advm-ex311_14.htm Edgar Link pending
advm-ex312_13.htm Edgar Link pending
advm-ex321_12.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending